Kura Oncology, Inc.

Contributing Author

Recent Articles by Kura Oncology, Inc.

Dec-08	Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML KURA GlobeNewswire
Dec-03	Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia KURA GlobeNewswire
Dec-02	First U.S. Commercial Sale of KOMZIFTI Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin KURA GlobeNewswire
Nov-25	KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML) KURA GlobeNewswire
Nov-13	Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia KURA GlobeNewswire
Nov-12	Kura Oncology to Participate in Upcoming Investor Conference KURA GlobeNewswire
Nov-07	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Nov-04	Kura Oncology Reports Third Quarter 2025 Financial Results KURA GlobeNewswire
Nov-03	Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin KURA GlobeNewswire
Nov-03	Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting KURA GlobeNewswire
Oct-28	Kura Oncology to Report Third Quarter 2025 Financial Results KURA GlobeNewswire
Oct-24	Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin KURA GlobeNewswire
Oct-18	Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress KURA GlobeNewswire
Oct-03	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Oct-01	Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) KURA GlobeNewswire
Sep-29	Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) KURA GlobeNewswire
Sep-25	Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology KURA GlobeNewswire
Sep-24	Kura Oncology to Participate in Upcoming Investor Conference KURA GlobeNewswire
Sep-16	Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types KURA GlobeNewswire
Sep-05	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Sep-03	Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program KURA GlobeNewswire
Aug-28	Kura Oncology to Participate in Three Upcoming Investor Conferences KURA GlobeNewswire
Aug-07	Kura Oncology Reports Second Quarter 2025 Financial Results KURA GlobeNewswire
Aug-04	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jul-31	Kura Oncology to Report Second Quarter 2025 Financial Results KURA GlobeNewswire
Jul-03	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jun-12	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress KURA GlobeNewswire
Jun-06	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jun-02	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting KURA GlobeNewswire
Jun-01	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML KURA GlobeNewswire
May-22	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting KURA GlobeNewswire
May-20	Kura Oncology to Participate in Three Upcoming Investor Conferences KURA GlobeNewswire
May-14	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress KURA GlobeNewswire
May-06	Kura Oncology to Participate in Bank of America Securities Healthcare Conference KURA GlobeNewswire
May-02	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
May-01	Kura Oncology Reports First Quarter 2025 Financial Results KURA GlobeNewswire

Kura Oncology, Inc.

Recent Articles by Kura Oncology, Inc.

Upgrade your FINVIZ experience